Asia Pacific Montelukast Intermediate Market Size & Outlook, 2026-2034

Asia Pacific Montelukast Intermediate Market Insights

Reed Intelligence analysis indicates that the Asia Pacific Montelukast Intermediate Market size, which was USD 1.93 Million in 2025, is projected to attain USD 2.96 Million by 2034.
The market is expected to register a CAGR of 4.86% over the period 2026–2034.
In 2025, GMP emerged as the dominant By Type based on market size.
Non-GMP is projected to register the fastest growth, positioning it as the most attractive By Type segment over the forecast horizon.

Other Key Findings

Asia Pacific represented 24.34% of the global Montelukast Intermediate Market size in 2025.
By 2034, United States is estimated to hold the largest position in the global market in terms of size.
Japan is estimated to remain the fastest-growing market in Asia Pacific, advancing to USD 0.39 Million by 2034.

Report Summary

Report Scope	Details
Base Year for Study	2025
Study Period	2022-2034
Historical Period	2022-2024
Forecast Period	2026-2034
Market Size In 2025	USD 1.93 Million
Market Size In 2034	USD 2.96 Million
Largest segment	GMP
Units	Revenue in USD Million
CAGR	4.86% (2026-2034)
Segmnetation Covered
Asia Pacific	China India Japan South Korea Taiwan Australia Singapore South East Asia
By Type	GMP Non-GMP
By Applications	Asthma Bronchospasm Allergic Rhinitis Urticaria
By End-User	Pharmaceutical and Biotechnological Companies Laboratories Others
Report Coverage	Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends

Asia Pacific Montelukast Intermediate Market Country 2026-2034 (USD Million)

Asia Pacific	2022	2023	2024	2025	2026	2027	2028	2029	2030	2031	2032	2033	2034
China	XX.x	XX.x	XX.x	0.73	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
India	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
Japan	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
South Korea	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
Taiwan	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
Australia	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
Singapore	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
South East Asia	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
Total	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x

Source: RI Analysis Company Publications, Primary Interviews.

Asia Pacific Montelukast Intermediate Market By Type 2026-2034 (USD Million)

By Type	2022	2023	2024	2025	2026	2027	2028	2029	2030	2031	2032	2033	2034
GMP	XX.x	XX.x	XX.x	1.07	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
Non-GMP	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
Total	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x

Source: RI Analysis Company Publications, Primary Interviews.

Asia Pacific Montelukast Intermediate Market By Applications 2026-2034 (USD Million)

By Applications	2022	2023	2024	2025	2026	2027	2028	2029	2030	2031	2032	2033	2034
Asthma	XX.x	XX.x	XX.x	0.78	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
Bronchospasm	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
Allergic Rhinitis	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
Urticaria	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
Total	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x

Source: RI Analysis Company Publications, Primary Interviews.

Asia Pacific Montelukast Intermediate Market By End-User 2026-2034 (USD Million)

By End-User	2022	2023	2024	2025	2026	2027	2028	2029	2030	2031	2032	2033	2034
Pharmaceutical and Biotechnological Companies	XX.x	XX.x	XX.x	0.97	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
Laboratories	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
Others	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
Total	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x

Source: RI Analysis Company Publications, Primary Interviews.

Author :

Reed Intelligence Research Team

The Reed Intelligence Research Team brings together over 15+ years of collective experience in market research, data analytics, and strategic consulting. Comprising seasoned analysts, economists, and industry specialists, the team delivers precise, data-driven insights across sectors including technology, healthcare, energy, manufacturing, and consumer goods. By combining domain expertise with modern analytical tools, they ensure each report meets the highest standards of accuracy and relevance.